

**SWHP Pharmacy and Therapeutics Committee Medicare Part D Updates**

October 2018

The SWHP P&T Committee conducted a meeting on **10/23/2018** and made the following changes to the Medicare Part D formularies.

**FORMULARY CHANGES**

There are no formulary changes applicable to the Medicare Part D formularies at this time.

**SWHP YEAR-TO-DATE FORMULARY GENERIC RELEASES (generic drug is available at copay listed once drug is available on the market)**

Therapeutic Class	Generic Name	For Brand Name	Formulary Status	Available Date
Agents to treat multiple sclerosis	Dalfampridine	Ampyra	Tier 5	November 2018
Hormone replacement agents	testosterone	Androgel 1.62%	Tier 2	October 2018
Central nervous system agents	clobazam	Onfi	Tier 4	October 2018
Anthelmintics	albendazole	Albenza	Tier 2	October 2018
Topical immune modulator	imiquimod	Zyclara	Tier 5	August 2018
GI anti-inflammatory agent	mesalamine enema	Rowasa SFRowasa	Tier 2	August 2018
Cholesterol reducers	colesevelam powder pack	Welchol	Tier 4	May 2018
Antivirals	ritonavir	Norvir	Tier 2	March 2018
Anticonvulsants	tiagabine	Gabitril	Tier 4	March 2018
Alzheimer's agents	memantine extended-release	Namenda XR	Tier 2	February 2018
Estrogens	estradiol 0.01% vaginal cream	Estrace	Tier 2	January 2018

**YEAR-TO-DATE FORMULARY CHANGES**

Formulary Tiers:

Tier 1: Preferred Generic, Tier 2: Generic, Tier 3: Preferred Brand, Tier 4: Brand, Tier 5: Specialty

PA= Prior Authorization

★ Prior Authorization Required for B vs. D Determination

Therapeutic Class	Medication	Formulary Changes	Formulary Alternatives	Effective date
Antineoplastics	<b>Tibsovo Braftovi</b>	Tier 5		10/1/2018
Antivirals	<b>Symtuza</b>	Tier 5		10/1/2018
Antineoplastics	<b>Mektovi</b>	Tier 5		10/1/2018
Antineoplastics	<b>Yonsa</b>	Tier 5		8/1/2018
Antipsoriatic agents	<b>Tremfya</b>	Tier 5 PA Required		7/1/2018
Antivirals	<b>Symfi Lo Symfi Cimduo Biktarvy</b>	Tier 5		6/1/2018
Antineoplastics	<b>Erleada</b>	Tier 5		6/1/2018
C1-esterase inhibitors	<b>Berinert</b>	Tier 5 PA Required		5/1/2018
Antivirals	<b>Vemlidy</b>	Tier 5		4/1/2018
Antiretrovirals	<b>Juluca</b>	Tier 5		3/1/2018
Hepatitis C antivirals	<b>Mavyret</b>	Tier 5 PA Required		1/1/2018
Bone formation stimulating agents	<b>Tymlos</b>	Tier 5 PA Required		1/1/2018
Diabetic therapy	<b>Jardiance Synjardy Invokana Invokamet</b>	Tier 3		1/1/2018

Formulary Tiers:

Tier 1: Preferred Generic, Tier 2: Generic, Tier 3: Preferred Brand, Tier 4: Brand, Tier 5: Specialty

PA= Prior Authorization

★ Prior Authorization Required for B vs. D Determination